Is there a disease-modifying drug for juvenile chronic arthritis?
Rooney
M
M
Molecular Rheumatology Section, MRC, Clinical Research Centre, Harrow, Middlesex.
D000284:Administration, Oral; D000962:Antimalarials / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D002648:Child; D005544:Forecasting; D006046:Gold / Q000627:therapeutic use; D006801:Humans; D007116:Immunization, Passive; D008727:Methotrexate / Q000627:therapeutic use; D010396:Penicillamine / Q000627:therapeutic use; D012219:Rheumatology / Q000639:trends; D012460:Sulfasalazine / Q000627:therapeutic use
D000962:Antimalarials; D012460:Sulfasalazine; D006046:Gold; D010396:Penicillamine; D008727:Methotrexate